The downgrade from Jefferies, a reputable financial services company, from Buy to Hold indicates a less optimistic outlook on Medpace's future performance. The reduction in the price target from $415 to $345 suggests a significant decrease in expected valuation, likely leading to a negative short-term impact on the stock price.